Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Deitmar Berger effective as of May 7, 2018.
The compensation committee of Atara's board of directors granted Dr. Berger a stock option to purchase 85,000 shares of Atara’s common stock, and restricted stock units to acquire 50,000 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Dr. Berger entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $42.05, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 7, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-410-3012
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
